Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61K31/355—Tocopherols, e.g. vitamin E
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention is directed to formulations comprising one or more alkaloids. More specifically but not exclusively it relates to formulations comprising one or more alkaloids and one or more phosphate derivatives of electron transfer agents. Background of the invention
• alkaloids there is a long history of the use of alkaloids for medicine. These compounds were originally extracted from plants and include nitrogenous compounds having physiological actions on humans as drugs and poisons.
• alkaloids as used in this description and in the claims includes all natural and synthetic active compounds containing primary, secondary or tertiary amine substituents. The amine may be incorporated into one or two rings, but non-cyclic structures are also included. For example, this includes :- • tertiary amines which:-
• alkaloids are not water soluble but are soluble in organic solvents. However, all alkaloids are basic and will combine with acids to form crystalline salts which are usually at least partially water soluble. Typically, alkaloids are administered as salts either orally or by intravenous injection.
• the alkaloids are a class of drugs that are not commonly administered transdermally because the hydrophilic nature of the salts usually limits transdermal transport. Morphine and atropine are examples of clinically useful alkaloids that are not administered transdermally. Further, it is desirable to improve oral delivery of alkaloids since some of them are thought to act through the lymphatic system. Topical administration
• Topical administration refers to the application of a drug directly to a part of the body and includes transdermal administration (application to the skin) and buccal administration (application to the inside of the mouth).
• the skin is the largest organ of the body and functions to protect the internal organs from external chemical, physical and pathological hazards. Normal skin is divided into three layers: the epidermis, the dermis, and subcutaneous tissue.
• the outer cornified layer of the epidermis, the stratum corneum possesses properties of strength, flexibility, high electrical impedance and dryness that retards penetration and proliferation of micro-organisms.
• the stratum corneum is also the principle barrier to transdermal drug absorption.
• transdermal delivery includes the application of drugs in the pure state or as formulations which typically include substances that enhance the rate of transport through the skin.
• transdermal delivery was as ointments, creams, poultices and plasters to give effective contact with the skin. More recently, the technology has been improved by making the plaster into a "patch" which has better adhesion to the skin and improved control over the rate of transport.
• Transdermal delivery has been recognized to offer several potential benefits including achieving blood levels similar to those achieved by slow intravenous infusion but without the inconvenience; better control of absorption and metabolism compared to oral administration; continuity of drug effect especially of drugs with short half lives; equivalent efficacy with reduced drug dosage due to by-pass of hepatic first pass elimination; lower risk of under or overdosing; and better patient compliance through simplification of a dosage regime.
• Not every drug can be administered transdermally at a rate sufficiently high enough to achieve blood levels that are therapeutically beneficial for systemic medication.
• Drugs with similar molecular weights and sizes for example may absorb across the skin at different rates.
• Skin enhancers and various formulation techniques have been developed to improve drug absorption through the skin. But concern has been raised with respect to long term risk because increased drug permeability is achieved at the cost of damaging a fundamentally important protective layer of the skin.
• transdermal delivery systems capable of delivering alkaloids.
• buccal delivery avoids metabolism by the liver which can be a problem when drugs are administered orally.
• the drug is formulated in a lozenge which is placed under the tongue.
• the lining of the mouth does not have an equivalent of the stratum corneum on the skin so it is not as difficult to administer drugs by buccal delivery, but this method of administration is not commonly used because the rate of transport may be low, achieving an ineffective result if the buccal membranes do not allow permeation or active transport.
• PCT/AU03/00998 discloses a carrier for pharmaceuticals wherein the carrier comprises a complex of a phosphate derivative of a pharmaceutically acceptable compound, for example, laurylaminodipropionic acid tocopheryl phosphates.
• PCT/AU03/00998 discloses that the tocopheryl phosphate is complexed to a complexing agent selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
• This carrier has been shown to improve the topical administration of testosterone, estrogen, atropine and morphine. However, in relation to morphine and atropine, further improvement in skin penetration was desired.
• Oral administration has been shown to improve the topical administration of testosterone, estrogen, atropine and morphine. However, in relation to morphine and atropine, further improvement in skin penetration was desired.
• Oral administration has been shown to improve the topical administration of testosterone, estrogen, atropine and morphine.
• an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of
• the phosphate derivative of a electron transfer agent is selected from the group comprising one or more phosphate derivatives of tocopherol.
• the alkaloid formulation is administered topically or orally.
• a method for improving the efficacy of an alkaloid comprising the step of reacting the alkaloid with one or more phosphate derivative of one or more electron transfer agents.
• the present invention also provides for the use of the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents, together with excipients in the manufacture of a formulation.
• the present invention also provides a pharmaceutical composition comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents, such as phosphate derivatives of tocopherol.
• the alkaloid is selected from the group consisting of tertiary amines which are
• the alkaloid is selected from the group consisting of atropine, quinine, opioids such as morphine, fentanyl, nicotine, fenspiride, flurazepan and codeine.
• electron transfer agents is used herein to refer to the class of chemicals which may be phosphorylated and which (in the non-phosphorylated form) can accept an electron to generate a relatively stable molecular radical or accept two electrons to allow the compound to participate in a reversible redox system.
• classes of electron transfer agent compounds that may be phosphorylated include hydroxy chromans including alpha, beta, gamma and delta tocols in enantiomeric and racemic forms; quinols being the reduced forms of vitamin Kl and ubiquinone; hydroxy carotenoids including retinol; calciferol and ascorbic acid.
• the electron transfer agent is selected from the group consisting of tocopherol and other tocols, retinol, vitamin Kl and mixtures thereof. More preferably, the electron transfer agent is selected from the group consisting of the tocols and mixtures thereof.
• the tocols include all isomers of derivatives of 6:hydoxy 2:methyl chroman (see structure below) where Rj, R 2 and R 3 may be hydrogen or methyl
• R 4 is substituted by 4:8:12 tri-methyl tridecyl group and includes various stereoisomers and optical isomers (chiral centres are indicted by the *).
• R/j is substituted by 4:8:12 tri-methyl trideca-3:7:l 1 triene group and the 2 position may be stereoactive as R or S stereoisomers.
• the electron transfer agent is oc-tocopherol.
• phosphate derivatives is used herein to refer to compounds covalently bound by means of an oxygen to the phosphorus atom of a phosphate group thus forming a carbon -oxygen -phosphorous bond.
• the oxygen atom is typically derived from a hydroxyl group on the electron transfer agent.
• the term includes the acid forms of phosphorylated electron transfer agents, salts of the phosphates including metal salts such as sodium, magnesium, potassium and calcium and any other derivative where the phosphate proton is replaced by other substituents such as ethyl or methyl groups or phosphatidyl groups.
• the term includes mixtures of phosphate derivatives, especially those which result from phosphorylation reactions, as well as each of the phosphate derivatives alone.
• the term includes a mixture of mono-tocopheryl phosphate (TP) and di- tocopheryl phosphate (T2P) as well as each of TP and T2P alone. Suitable mixtures are described in international patent application no PCT/AUO 1/01475.
• phosphate derivatives does not include complexes of the phosphate derivatives with a complexing agent selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
• the one or more phosphate derivatives of one or more electron transfer agents is selected from the group consisting of mono-tocopheryl phosphate, di-tocopheryl phosphate
• the one or more phosphate derivatives of one or more electron transfer agents is a mixture of mono-tocopheryl phosphate and di-tocopheryl phosphate.
• Phosphatidyl derivatives are amino alkyl derivatives of organic phosphates. These derivatives may be prepared from amines having a structure of R ⁇ R 2 N(CH 2 ) n OH wherein n is an integer between 1 and 6 and Ri and R 2 may be either H or short alkyl chains with 3 or less carbons. Ri and R 2 may be the same or different.
• the phosphatidyl derivatives are prepared by displacing the hydroxyl proton of the electron transfer agent with a phosphate
• phosphatidyl derivative entity that is then reacted with an amine, such as ethanolamine or N,N' dimethylethanolamine, to generate the phosphatidyl derivative of the electron transfer agent.
• an amine such as ethanolamine or N,N' dimethylethanolamine
• One method of preparation of the phosphatidyl derivatives uses a basic solvent such as pyridine or triethylamine with phosphorous oxychloride to prepare the intermediate which is then reacted with the hydroxy group of the amine to produce the corresponding phosphatidyl derivative, such as P cholyl P tocopheryl dihydrogen phosphate.
• the alkaloid formulation may be administered to humans or animals through a variety of dose forms such as supplements, enteral feeds, parenteral dose forms, suppositories, nasal delivery forms, dermal delivery including patches and creams, buccal delivery forms. Oral or buccal delivery may specifically suit alkaloids which have low water solubility.
• oral alkaloid formulations according to the invention further comprise an enteric coating.
• the enteric coating protects the complexes from the acidic environment in the stomach.
• Oral formulations may take the form of tablets, powders, chewable tablets, capsules, oral suspensions, suspensions, emulsions or fluids, children's formulations, enteral feeds, nutraceuticals, and functional foods.
• the dose form may further include any additives routinely used in preparation of that dose form such as starch or polymeric binders, sweeteners, coloring agents, emulsifiers, coatings and the like.
• Another suitable additive is a complex of a phosphate derivative of an electron transfer agents may also be utilized where additional properties such as improved stability or deliverability may be useful.
• complexes of phosphate derivatives refers to the reaction product of one or more phosphate derivatives of electron transfer agents with one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids as disclosed in international patent application no PCT/AUO 1/01476, incorporated herein by reference. If such an additive was used, it would be important to ensure that there was excess electron transfer agent present in the formulation.
• Other suitable additives will be used, it would be important to ensure that there was excess electron transfer agent present in the formulation.
• Other suitable additives will be used, it would be important to ensure that
• Figure 1 Effect of various atropine formulations on heart rate in pigs. Data are cumulative averages over 10 minute periods and have been corrected for basal (average of
• Figure 2 Typical differential of heart rate versus time curve. Data are from pig 1 during replicate 1 who was treated with preparation C (ie the very first pig used). The treatment application commenced at 0 minutes and continued for 6 minutes. The period over which differentials were averaged is indicated by the straight lines.
• Figure 3 Effect of various base creams on heart rate in pigs. Data are cumulative averages over 10 minutes periods and have been corrected for basal (average of 1 h before application) using covariate analyses.
• FIG 4 Typical heart rate versus time curve. Data are from pig 1 during replicate 1 who was treated with preparation C (ie the very pig used). The treatment application commenced at 0 minutes and continued for 6 minutes. The period over which differentials were averaged is indicated by the straight lines.
• Figure 5 Effect of treatment and time flinch response after heat probe application
• Figure 6 Effect of morphine 1.35, 2.7 and 5.4 mg/kg in TPM-01/M formulation on paw withdrawal latency, tested up to 8 hours.
• Example 1 investigates the transdermal delivery to pigs of atropine in a formulation according to the invention.
• This experiment investigated the effects of dermal penetration of atropine when applied in gel form on heart rate of pigs.
• Methods and materials Atropine (20 mg/kg) was formulated in the following base creams for testing.
• all of the creams contained the following: 12% Ultrez- 10 Carbomer-3% solution, 0.25% Triethanolamine, 0.1% Surcide DMDMH and Deionized Water up to 100%.
• Compositions f, H and J when combined with atropine produce a formulation according to the invention.
• Compositions B, D and E produce formulations according to the prior art and compositions A, C and I illustrate the effect of the excipients.
• This belt protected the transmitter from physical damage and included a pocket for storage of the monitor recording unit (similar to a wristwatch) during the recording period.
• Treatment appUcation was begun at least 1 h after the commencement of heart rate recording.
• Three staff wearing protective rubber gloves applied each of the test formulations in 5 ml syringes. This involved rubbing the products into the skin of the pig while an assistant directed warm air from an electric hair dryer onto the treatment area. Rubbing was discontinued after approximately 8 to 10 minutes when the skin surface became tacky to touch.
• Table 1 demonstrates that Formulation G is consistently more effective than a similar concentration of atropine in compositions containing the lauryliminodipropionate-tocopheryl phosphates.
• Table 2 shows that there is a consistent increased efficacy of formulation G versus formulation H for log peak rate, log time to peak and, importantly, log ascending slope and log descending slope.
• Example 2 This example investigated the effect of transdermal delivery to pigs of morphine.
• the skin of pigs has similar properties to human skin and as such the pig is an excellent model for studying dermal delivery of drugs.
• Flinch test data were analysed by REML (Residual maximum likelihood) with treatment and time as the fixed model and pig, replicate and flinch time at time zero as the random model. Data were initially analysed raw but because there were some skewed data at 6 h they were also log-transformed for analyses. Either analyses provided essentially the same interpretation. The following formulations were tested:
• the flinch time for pigs treated with preparation AGM had a greater flinch time than any of the other treatments (2.63, 2.88, 4.82 and 3.17 seconds for treatments AG, AH, AGM and AHM, Table 4).
• the response was greatest at 6 h after treatment ( Figure 5) suggesting a sustained effect, particularly when compared to the control AG.
• the flinch test was 133% greater at 6 h in pigs treated with AGM compared to AG.
• AHM had a greater flinch time at 2 h after treatment when compared to the control AH, but this was not sustained. AHM did not provide the sustained results which were obtained with AGM.
• transdermal delivery of morphine in a formulation according to the invention provides rapid and sustained analgesia as measured by a delay in the tail flinch response to a heat treatment at 1 to 6 h. Further, the formulation according to the invention caused no inflammation, thus it appears possible to allow prolonged dermal contact without causing irritation.
• Table 4 Effect of treatment and time flinch response after heat probe application (seconds) 1
• the base gels used as controls contained all of the ingredients except for the tocopheryl phosphate. Vital ET was not used in this experiment and is listed here as a comparison of
• Test Method The plantar analgesiometer is designed for rapid and efficient screening of analgesia levels
• the device is used to apply a heat source ( ⁇ 45°C from an
• the hot plate provides a constant surface temperature, with a
• the animal is placed on a hot plate, confined by a clear acrylic cage which surrounds the plate and paw-lick response is monitored. An increased time period before paw-lick response indicating analgesia.
• Rats had a hair removal cream applied to a dorsal hindquarter area of skin (under anaesthesia) at least 24 hours prior to any transdermal patch application.
• Conscious Sprague Dawley rats ( ⁇ 400 grams) received mo ⁇ hine at a dose of 10 mg mo ⁇ hine HC1 per kg body weight.
• the formulation contained 10% w/w mo ⁇ hine.HCl, and for a 0.2 kg rat the amount applied was 20 mg of formulation that contained 2 mg mo ⁇ hine.HCl.
• a single application was used in the morning, with measures of the analgesia made at various time-points.
• the skin area exposed to drug/vehicle was then covered with a Tegaderm patch. All animals underwent analgesic testing before and after mo ⁇ hine administration. Results:
• Figure 6 illustrates the results achieved with each of the formulations.
• the results show an increase in response time, indicating analgesia, in a dose-dependant manner.
• the control test of gel with mo ⁇ hine but no TPM show the essential requirement of TPM for the transdermal route to work. Results are expressed as change in withdrawal time compared to controls, where control values are from rats treated with incomplete formulations (i.e., no mo ⁇ hine or no TPM), as well as the zero-time values for rats treated with complete the formulation, TPM-01/M)
• the formulation used in this study contains TP/T2P mix (or TPM), mo ⁇ hine.HCl and other excipients as listed in table 5.
• the formulation did not contain any lauryldiaminoproprionic acid.
• Figure 6 shows a clear dose-response and a sustained affect.
• control ie, a control gel with base excipients only, and no mo ⁇ hine and no TP/T2P mix, and a control gel with base excipients and mo ⁇ hine but no TP/T2P
• the results show that mo ⁇ hine is best delivered when formulated with the TP/T2P mix.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Emergency Medicine (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Rheumatology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=34921028

Family Applications (1)

Country Status (14)

Cited By (10)

Families Citing this family (15)

Citations (5)

Family Cites Families (177)

• 2005
  • 2005-03-03 RU RU2006131997/15A patent/RU2477136C2/ru not_active IP Right Cessation
  • 2005-03-03 NZ NZ549567A patent/NZ549567A/en not_active IP Right Cessation
  • 2005-03-03 AT AT05706340T patent/ATE495730T1/de not_active IP Right Cessation
  • 2005-03-03 EP EP05706340A patent/EP1720551B9/en not_active Expired - Lifetime
  • 2005-03-03 DK DK05706340.6T patent/DK1720551T3/da active
  • 2005-03-03 WO PCT/AU2005/000307 patent/WO2005084678A1/en not_active Ceased
  • 2005-03-03 KR KR1020067017766A patent/KR101173159B1/ko not_active Expired - Fee Related
  • 2005-03-03 AU AU2005202477A patent/AU2005202477B2/en not_active Ceased
  • 2005-03-03 US US10/551,203 patent/US20060281716A1/en not_active Abandoned
  • 2005-03-03 JP JP2007501066A patent/JP4847437B2/ja not_active Expired - Fee Related
  • 2005-03-03 DE DE602005025979T patent/DE602005025979D1/de not_active Expired - Lifetime
  • 2005-03-03 BR BRPI0508125-4A patent/BRPI0508125A/pt not_active IP Right Cessation
  • 2005-03-03 CA CA2557354A patent/CA2557354C/en not_active Expired - Fee Related
• 2006
  • 2006-08-30 IL IL177781A patent/IL177781A/en not_active IP Right Cessation
• 2010
  • 2010-01-20 US US12/690,735 patent/US8529947B2/en not_active Expired - Fee Related

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events